Navigation Links
Personalizing revascularization strategy for STEMI patients is vital, EuroPCR panel finds
Date:5/21/2014

21 May 2014, Paris, France: A Great Debate at EuroPCR 2014 saw experts discussing the role of the two most valuable strategies to save the lives of ST-segment Elevation Myocardial Infarction (STEMI) patients: primary percutaneous coronary intervention (PCI) and thrombolysis.

Both these are effective treatments that actively save lives, and when there is no option for primary percutaneous coronary intervention, thrombolysis is the way to proceed, participants heard. The topic of the Great Debate, 'Primary PCI for STEMI: an emergency!' was selected ahead of the session by the interventional cardiology community, according to a vote on the EuroPCR website.

Thomas Cuisset, University Hospital, Marseille, France, noted that the goal of the session was to highlight the current clinical issues with the optimisation of primary PCI, and discuss the specifics of the technique, devices and adjunctive pharmacology.

"The spirit and core of the session was interaction between the facilitators and audience who sent in their questions throughout the session. Within this, we sought to highlight that primary PCI has to be a personalised intervention. Within the 'STEMI box', we are dealing with many very different patients and so the choice of drugs, vascular access and use (or not) of thromboaspiration, needs to be tailored to fit the patient," he said.

The final goal in STEMI is early revascularisation and in some geographies, for various reasons, primary PCI is delayed and therefore a pharmacoinvasive strategy can be a good alternative in such areas, the panel agreed.

Sajidah Khan, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa, emphasised that the efforts for treating STEMI comes from the recognition that the biggest impact on survival depends on establishing reperfusion within the first three hours of the onset of chest pain.

"The most powerful method of reducing mortality is to use whatever method you have at
'/>"/>

Contact: Isabelle Uzielli
iuzielli@europcr.com
EuroPCR
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Personalizing biologic treatment to individual patients with rheuatoid arthritis is cost-effective
2. Personalizing medicine: New American Chemical Society Prized Science video
3. Personalizing prostate specific antigen testing may improve specificity, reduce biopsies
4. Personalizing prostate cancer screenings
5. Results released for first multicenter study of hybrid revascularization
6. New ESC-EACTS guidelines on myocardial revascularization to be released at EuroPCR 2014
7. White House Drug Policy Shifts Strategy
8. Discovery suggests new combination therapy strategy for basal-like breast cancers
9. Strategy discovered to activate genes that suppress tumors and inhibit cancer
10. New drug strategy attacks resistant leukemia and lymphoma
11. VisionWare and Serco Partner to Enable ‘Digital by Default’ Strategy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... At the 7th Annual Mississippi Addiction Conference ... met today in Jackson, Mississippi to listen to keynote ... numerous respected speakers will be William S. Jacobs, ... pain medications have had in today’s opiate overdose and ... is hard to believe that much of the current ...
(Date:3/5/2015)... University of Western States (UWS), ... has launched a new center of excellence to ... Northwest Center for Lifestyle and Functional Medicine aim ... and conduct research in the areas of lifestyle ... The center will target efforts on the UWS ...
(Date:3/5/2015)... 05, 2015 Dr. Jonathan Glashow a ... ) has been named by Castle Connolly ... area. Dr. Glashow has been selected by Castle Connolly ... the top specialty care doctors in the tri-state metropolitan ... Connolly program, which carefully screens and selects doctors through ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 Today, ... now running on 100% pollution-free electricity through a ... , As an Arcadia Power Clean Energy ... (EPA) Green Power Partnership requirements, joining national brands ... also purchase clean energy. Earth Source Organics joins ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 Think it’s tough ... even tougher to get them to brush their teeth. That’s ... parents released today by Delta Dental(1) in conjunction with National ... (45 percent) say getting kids to brush their teeth is ... to do. That’s slightly higher than getting children to eat ...
Breaking Medicine News(10 mins):Health News:National Addiction Treatment Expert William S. “Bill” Jacobs, Md Speaks At Prestigious 7th Annual Mississippi Addiction Conference 2Health News:National Addiction Treatment Expert William S. “Bill” Jacobs, Md Speaks At Prestigious 7th Annual Mississippi Addiction Conference 3Health News:University of Western States Launches Northwest Center for Lifestyle and Functional Medicine 2Health News:Dr. Jonathan Glashow, NYC Orthopedic Surgeon, Named Top Doctor: New York Metro Area 2Health News:Earth Source Organics to Run on Clean Energy from Arcadia Power 2Health News:Delta Dental Survey Says Parents Have Harder Time Getting Kids to Brush than to Eat Vegetables 2Health News:Delta Dental Survey Says Parents Have Harder Time Getting Kids to Brush than to Eat Vegetables 3
... method cuts death risk, study finds , WEDNESDAY, Aug. ... who receive early non-invasive ventilation after a breathing tube ... failure or die, a Spanish study has found. , ... of them had high levels of carbon dioxide in ...
... behind progress, study finds , THURSDAY, Aug. 13 (HealthDay ... younger people, new research shows. , And while cancer ... the United States, topping heart disease, that is because ... cancer. , "Older Americans have only experienced decreased [cancer] ...
... YORK, Aug. 13 The International Longevity Center, with support ... $20,000 grants for caregiver training programs. , , ... Initiative grants are part of the Caregiving Project for ... the Schmieding Center for Senior Health and Education. The initiative ...
... , , BALTIMORE, Aug. ... Maryland, the Black Nurses Association of Baltimore and the Greater ... Health Insurer Code of Conduct from the American Medical Association. ... portion of the state,s racial and ethnic minorities, including African ...
... , THOUSAND OAKS, Calif., Aug. 13 ... data from the submitted Biologic License Applications (BLAs) for denosumab for ... treatment of bone loss in breast and prostate cancer patients undergoing ... Administration,s (FDA) Advisory Committee for Reproductive Health Drugs (ACRHD). , ...
... RICHMOND, Va., Aug. 13 Insmed Inc. (Nasdaq: ... second quarter and six-months ended June 30, 2009. , , ... were $3.0 million, up from $2.7 million for the corresponding period ... grant revenue related to the IPLEX(TM) myotonic muscular dystrophy ("MMD") clinical ...
Cached Medicine News:Health News:Ventilation After Breathing Tube Removal May Alter Outcomes 2Health News:Cancer Deaths Declining, Especially Among Young 2Health News:Cancer Deaths Declining, Especially Among Young 3Health News:Fifteen Community Colleges Win Awards for Innovative Caregiving Training Programs 2Health News:Fifteen Community Colleges Win Awards for Innovative Caregiving Training Programs 3Health News:Fifteen Community Colleges Win Awards for Innovative Caregiving Training Programs 4Health News:Fifteen Community Colleges Win Awards for Innovative Caregiving Training Programs 5Health News:Leading African American Groups Call On Health Insurers to Dismiss Restrictive Practices 2Health News:Leading African American Groups Call On Health Insurers to Dismiss Restrictive Practices 3Health News:Amgen to Discuss Denosumab Data at Today's Advisory Committee for Reproductive Health Drugs 2Health News:Amgen to Discuss Denosumab Data at Today's Advisory Committee for Reproductive Health Drugs 3Health News:Amgen to Discuss Denosumab Data at Today's Advisory Committee for Reproductive Health Drugs 4Health News:Amgen to Discuss Denosumab Data at Today's Advisory Committee for Reproductive Health Drugs 5Health News:Amgen to Discuss Denosumab Data at Today's Advisory Committee for Reproductive Health Drugs 6Health News:Amgen to Discuss Denosumab Data at Today's Advisory Committee for Reproductive Health Drugs 7Health News:Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2009 2Health News:Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2009 3Health News:Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2009 4Health News:Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2009 5Health News:Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2009 6Health News:Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2009 7Health News:Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2009 8Health News:Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2009 9
(Date:3/5/2015)... March 5, 2015  ANI Pharmaceuticals, Inc. ("ANI") ... it has acquired the approved abbreviated new drug ... 100mg and 150mg, previously marketed by Teva Pharmaceuticals.  ... this product was approximately $39 million in 2014. ... President and CEO of ANI Pharmaceuticals, stated, "This ...
(Date:3/5/2015)... - Cross reference: Picture is available via ... Hitachi Medical Systems Europe è lieta di ... 2015. Si tratta di un sistema di RM ... migliora la capacità diagnostica dei sistemi già esistenti e ... Le nuove funzionalità di OASIS permettono una migliore gestione ...
(Date:3/5/2015)... DUBLIN , Mar. 05, 2015 Research ... announced the addition of the "Global Pharma ... and Cost Optimization Plays Major Role In Shaping ... report to their offering. Strategy ... resulting in healthy Cash position- Will accelerate Next ...
Breaking Medicine Technology:ANI Pharmaceuticals Acquires Generic Drug Product from Teva Pharmaceuticals 2ANI Pharmaceuticals Acquires Generic Drug Product from Teva Pharmaceuticals 3Hitachi Medical Systems Europe lancia la nuova generazione di OASIS*: Il sistema di RM aperta ad alto campo da 1.2 T. Ancora più valore al paziente 2Hitachi Medical Systems Europe lancia la nuova generazione di OASIS*: Il sistema di RM aperta ad alto campo da 1.2 T. Ancora più valore al paziente 3Hitachi Medical Systems Europe lancia la nuova generazione di OASIS*: Il sistema di RM aperta ad alto campo da 1.2 T. Ancora più valore al paziente 4Global Pharma US & EU Outlook 2015: First -In-Class Innovations and Cost Optimization Plays Major Role In Shaping Up Business for Large Cap Pharmaceutical Companies 2Global Pharma US & EU Outlook 2015: First -In-Class Innovations and Cost Optimization Plays Major Role In Shaping Up Business for Large Cap Pharmaceutical Companies 3
... 2011 Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical ... by the U.S. Food and Drug Administration (FDA) that ... Insmed,s phase 3 clinical trials for ARIKACE® (liposomal amikacin ... Pseudomonas lung infections. Insmed has not yet received ...
... 2011 /PRNewswire-Asia/ -- Phase 2a trial validates Biotron ... First- in - class new, ... Full data to be presented to scientific conference in December ... headline results from its landmark Phase 2a trial of its lead drug candidate, BIT225 ...
Cached Medicine Technology:Insmed Incorporated Provides Regulatory Update 2Insmed Incorporated Provides Regulatory Update 3Hepatitis C Phase 2A Trial Positive Results 2Hepatitis C Phase 2A Trial Positive Results 3
... Channel Implants, designed to accept ... surgeon with an excellent reconstructive ... and floor blowout defects. Each ... placement of one or more ...
... The Medpor Inferior Orbital Rim implant can ... and is designed to be trimmed to ... A small flange allows it to rest ... orbital floor. This flange allows easier positioning ...
Flattened points in vertical plane, straight shafts, cross action, round handle....
Nucleus chopper....
Medicine Products: